FDA granted nod to 37 Pharma firms for azithromycin

AHMEDABAD: Various Pharmaceutical companies are induldged in manufacturing of the azithromycin along with hydroxychloroquine (HCQ) as used in the treatment novel coronavirus. Gujarat Food and Drug Control Administration (FDCA) has granted permissions to 37 firms since march for the manufacturing of the antibiotic in Gujarat.

Dr H G Koshia, commissioner, Gujarat FDCA said, “Azithromycin has been included into the standard treatment protocol for Covid-19. As many as 66 product licences have been issued to 37 pharma companies for azithromycin during past two months.”
The various companies are Vega Biotec, Gujarat Medicraft, Care-well Healthcare, Curis Lifesciences Private Ltd, Galen Pharma, Rusan Pharma and Unimed Pharma Ltd.

At present, 629 pharmaceutical companies in Gujarat are involved in manufacturing of azithromycin and its raw material (active pharmaceutical ingredient). 1,397 product licences have been issued, so far. Vadodara-based Alembic Pharmaceuticals Ltd is the leading company in manufacturing azithromycin.

The companies involved in making HCQ has also jumped threefold in Gujarat for growing demand of this anti-malarial drug across the world. Around 68 companies have received Gujarat FDCA nod to manufacture HCQ in the state since the Covid-19 outbreak in the country. Earlier, the number of companies was only 28.

  • Related Posts

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    The Team Meticulously averted the Risk of Thrombosis, Husband was Donor Delhi/NCR : Doctors at Yashoda Medicity have successfully performed a high-risk kidney transplant in a 28-year-old woman with Antiphospholipid…

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    Avacta, a UK-based clinical stage biotech, is differentiated clinical-stage oncology specialist, increasingly defined by continuing progress with its second-generation pre|CISION tumour-activated Peptide Drug Conjugate (PDC) platform. The lead Gen Two…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

    Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

    Puresta launches EVERQ, AI-powered skin-health platform

    Puresta launches EVERQ, AI-powered skin-health platform

    Stem cell therapy for autism only in approved clinical trials: Centre

    Stem cell therapy for autism only in approved clinical trials: Centre